Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Public Health Genomics and Precision Health Knowledge Base (v5.9)

Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

HuGE Navigator|HuGE Literature Finder|PHGKB

HuGE Literature Finder

Records 1-13

Query Trace: Diarrhea and DPYD[orginal query]

Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. Journal of gastrointestinal oncology 2018 Jun 9 (3): 416-424. Khushman Moh'd, Patel Girijesh Kumar, Hosein Peter Joel, Laurini Javier Ariel, Cameron Daniel, Clarkson David Roland, Butler Thomas Wayne, Norden Carole Wiseman, Baliem Wilma, Jones Vanessa, Bhadkamkar Sanjyot, Nelson Cindy, Lee Frances, Singh Ajay P, Taylor William Similar articles in PubMed
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer chemotherapy and pharmacology 2017 Nov . Nahid Noor Ahmed, Apu Mohd Nazmul Hasan, Islam Md Reazul, Shabnaz Samia, Chowdhury Surid Mohammad, Ahmed Maizbha Uddin, Nahar Zabun, Islam Md Siddiqul, Islam Mohammad Safiqul, Hasnat Ab Similar articles in PubMed
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L Similar articles in PubMed
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber Similar articles in PubMed
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H Similar articles in PubMed
Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. International journal of clinical and experimental medicine 2014 7 (12): 5857-61. Sun Wenhui, Yan Chungen, Jia Shaochang, Hu Jianh Similar articles in PubMed
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013 Aug 14 (11): 1255-72. Terrazzino Salvatore, Cargnin Sarah, Del Re Marzia, Danesi Romano, Canonico Pier Luigi, Genazzani Armando Similar articles in PubMed
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 17 (10): 3455-68. Deenen Maarten J, Tol Jolien, Burylo Artur M, Doodeman Valerie D, de Boer Anthonius, Vincent Andrew, Guchelaar Henk-Jan, Smits Paul H M, Beijnen Jos H, Punt Cornelis J A, Schellens Jan H M, Cats Annemie Similar articles in PubMed
Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): 3606. Deenen M J, Cats A, Sechterberger M K, Severens J L, Smits P H M, Bakker R, Mandigers C M, Soesan M, Beijnen J H, Schellens J H Similar articles in PubMed
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian patients (pts) with 5-FU and capecitabine (CAP)-related toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e14588. Podoltsev N A, Saif M Similar articles in PubMed
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 May 26 (13): 2131-8. Schwab Matthias, Zanger Ulrich M, Marx Claudia, Schaeffeler Elke, Klein Kathrin, Dippon Jürgen, Kerb Reinhold, Blievernicht Julia, Fischer Joachim, Hofmann Ute, Bokemeyer Carsten, Eichelbaum Michel, Similar articles in PubMed
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Sep 7 (9): 2832-9. Raida M, Schwabe W, Häusler P, Van Kuilenburg A B, Van Gennip A H, Behnke D, Höffken Similar articles in PubMed
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L Similar articles in PubMed

File Formats Help:

How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?

Page last reviewed:Jul 30, 2019
Page last updated:Aug 15, 2019
Content source:

TOP